BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-612-7474423
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees86
OptionableNot Optionable
Bioamber (NYSE:BIOA) Frequently Asked Questions
What is Bioamber's stock symbol?
Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."
How were Bioamber's earnings last quarter?
Bioamber Inc (NYSE:BIOA) posted its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to analysts' expectations of $2.37 million. View Bioamber's Earnings History.
What price target have analysts set for BIOA?
1 equities research analysts have issued 1-year price targets for Bioamber's shares. Their predictions range from $1.75 to $1.75. On average, they expect Bioamber's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 13,571.9% from the stock's current price. View Analyst Price Targets for Bioamber.
What is the consensus analysts' recommendation for Bioamber?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioamber in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bioamber.
Has Bioamber been receiving favorable news coverage?
News articles about BIOA stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bioamber earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are Bioamber's key executives?
Bioamber's management team includes the folowing people:
- Raymond J. Land, Chairman of the Board (Age 72)
- Richard P. Eno, Chief Financial Officer, Director
- Mario Settino, Chief Financial Officer
- Michael A. Hartmann, Executive Vice President (Age 48)
- James Millis, Chief Technology Officer (Age 59)
- Robert Frost, Director
- Kurt W. Briner, Independent Director (Age 70)
- Heinz Haller, Independent Director (Age 62)
- Ellen B. Richstone, Independent Director (Age 65)
- Kenneth W Wall, Independent Director (Age 66)
How do I buy shares of Bioamber?
Shares of BIOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioamber's stock price today?
One share of BIOA stock can currently be purchased for approximately $0.0128.
What is Bioamber's official website?
How can I contact Bioamber?
Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected]
MarketBeat Community Rating for Bioamber (NYSE BIOA)
MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote "Outperform" if you believe BIOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
